metamizol-sf 500 mg roztwór do wstrzykiwań
sun-farm sp. z o.o. - metamizolum natricum monohydricum - roztwór do wstrzykiwań - 500 mg
pyralgina plus 400 mg + 60 mg + 40 mg tabletki powlekane
zakłady farmaceutyczne polpharma s.a. - metamizolum natricum monohydricum + coffeinum + drotaverini hydrochloridum - tabletki powlekane - 400 mg + 60 mg + 40 mg
pyretolek 500 mg tabletki powlekane
sun-farm sp. z o.o. - metamizolum natricum monohydricum - tabletki powlekane - 500 mg
benlek 500 mg + 38,75 mg + 50 mg tabletki
solinea sp. z o.o. sp.k. - metamizolum natricum monohydricum + thiamini hydrochloridum + coffeinum - tabletki - 500 mg + 38,75 mg + 50 mg
vemonis intense 400 mg + 60 mg + 40 mg tabletki powlekane
adamed pharma s.a. - metamizolum natricum + coffeinum + drotaverini hydrochloridum - tabletki powlekane - 400 mg + 60 mg + 40 mg
metamizol krka 500 mg/ml roztwór do wstrzykiwań / do infuzji
krka, d.d., novo mesto - metamizolum natricum monohydricum - roztwór do wstrzykiwań / do infuzji - 500 mg/ml
metamizol promedo 500 mg tabletki
promedo pharma products gmbh - metamizolum natricum monohydricum - tabletki - 500 mg
tavneos
vifor fresenius medical care renal pharma france - avacopan - microscopic polyangiitis; wegener granulomatosis - leki immunosupresyjne - tavneos, in combination with a rituximab or cyclophosphamide regimen, is indicated for the treatment of adult patients with severe, active granulomatosis with polyangiitis (gpa) or microscopic polyangiitis (mpa).
dialginum 500 mg proszek do sporządzania roztworu doustnego
chemax pharma ltd. - metamizolum natricum - proszek do sporządzania roztworu doustnego - 500 mg
nucala
glaxosmithkline trading services - mepolizumab - astma - preparaty do obturacyjne choroby dróg oddechowych, - severe eosinophilic asthmanucala is indicated as an add-on treatment for severe refractory eosinophilic asthma in adults, adolescents and children aged 6 years and older. chronic rhinosinusitis with nasal polyps (crswnp)nucala is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adult patients with severe crswnp for whom therapy with systemic corticosteroids and/or surgery do not provide adequate control. eosinophilic granulomatosis with polyangiitis (egpa)nucala is indicated as an add-on treatment for patients aged 6 years and older with relapsing-remitting or refractory eosinophilic granulomatosis with polyangiitis (egpa). hypereosinophilic syndrome (hes)nucala is indicated as an add-on treatment for adult patients with inadequately controlled hypereosinophilic syndrome without an identifiable non-haematologic secondary cause.